Cytokinetics (CYTK) news
Recent news
Cytokinetics, Incorporated: RBC raises target price to $113 from $112
RBC Capital Markets has raised its target price for Cytokinetics, Incorporated (CYTK) to $113 from $112, reflecting a slight upward adjustment in its valuation outlook for the biopharmaceutical company. The updated target suggests increased confidence in Cytokinetics' potential performance, though…
AInvest Wire · 4d agoCytokinetics shares up 1.4% premarket after co presents new late-stage data for heart drug at European Society of Cardiology
Cytokinetics, Incorporated (Nasdaq: CYTK) reported a 1.4% increase in premarket trading following the presentation of late-stage clinical data for its heart drug, aficamten, at the European Society of Cardiology. The company announced positive topline results from the ACACIA-HCM trial, a pivotal…
AInvest Wire · Aug 28, 2026Cytokinetics announces positive results from Acacia-HCM
AInvest Wire · Aug 28, 2026Cytokinetics - seeks injunction against litigation or infringement claims on Myqorzo(aficamten) - SEC filing
AInvest Wire · Aug 13, 2026Cytokinetics - Demands trial by jury on all triable issues - SEC filing
AInvest Wire · Aug 13, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.